



ADVISORY

No. 200

October 23, 2019

Brand Lyrica® Oral Solution Removal from DAW 6 Drug Program

The Office of Pharmacy Services (OPS), formerly known as the Maryland Medicaid Pharmacy Program, wants to alert you that effective Friday, Nov. 15, 2019 brand Lyrica® 20mg/ml oral solution will no longer be preferred over its generic equivalent (pregabalin 20mg/ml oral solution).

Claims for pregabalin 20mg/ml oral solution will be handled in the same manner as claims for other multisource medications.* Claims for brand Lyrica® 20mg/ml oral solution will adjudicate only if there is a prior authorization based on an approved Maryland Department of Health (MDH) Medwatch form, which can be found at:

<https://mmcp.health.maryland.gov/pap/docs/Maryland%20Medwatch%20Form.pdf>

***Please note: pregabalin 20mg/ml oral solution will remain a non-preferred medication on the OPS Preferred Drug List (PDL) and will require prior authorization by the prescriber.**

Please refer to our website for the complete PDL:

<https://mmcp.health.maryland.gov/pap/pages/Preferred-Drug-List.aspx>

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health **Maryland Office of Pharmacy Services** has developed the **Maryland Medicaid Pharmacy Program Advisory**.

To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations.

It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the MMPP representative at 410-767-1455.